Royalty Growth Drives Ligand's Q2 Revenue Up 34%; Full-Year Outlook Raised

summarizeSummary

Ligand's Q2 2026 revenue climbed 34% to $63.7M on robust royalty growth, net income reached $48.5M, and the company raised its full-year royalty outlook. The XOMA acquisition closed in July, doubling its royalty assets.

check_boxKey Events · Earnings and Guidance · LGND

• Q2 Revenue Up 34%

  Driven by a 32% increase in royalties to $48.0 million, total revenues and income reached $63.7 million, with Filspari, Ohtuvayre, and Zelsuvmi leading the charge.

• Net Income Surges to $48.5M

  Net income hit $48.5 million, or $2.22 per diluted share, compared to $4.8 million in Q2 2025, boosted by a $35.7 million non-cash gain from the fair value change in the Pelthos investment.

• Full-Year Royalty Guidance Raised

  Reflecting strong partner product sales and new royalty streams from recent transactions, management increased its 2026 royalty revenue guidance.

• XOMA Acquisition Closed

  On July 14, 2026, Ligand completed the $739 million acquisition of XOMA Royalty, doubling its royalty portfolio to over 200 assets and adding seven commercial products.

auto_awesomeAnalysis · LGND · Life Sciences

A 32% surge in royalties from key products—Filspari, Ohtuvayre, and Zelsuvmi—powered Ligand's total revenue to $63.7 million, a 34% jump. Net income swung dramatically to $48.5 million from $4.8 million a year ago, largely thanks to a $35.7 million non-cash gain tied to the Pelthos investment. Confidence in the portfolio prompted management to lift full-year royalty revenue guidance. The balance sheet is now fortified with $1.36 billion in cash and investments following a $700 million convertible note offering, and the transformative XOMA Royalty acquisition closed in July, doubling the royalty portfolio. While the quarter validates the royalty aggregation model at scale, the XOMA integration and convertible debt overhang introduce new risks to monitor.